Structure Therapeutics is trading 10.08% down at $42.57 after a broader risk-off session in U.S. equities, with geopolitical tensions, higher oil prices, tariffs, and shifting Federal Reserve expectations pressuring growth stocks.
- The September 8 clinical update was positive: aleniglipron produced up to 16.2% weight loss at 72 weeks.
- ACCG-2671 showed a roughly six-day half-life and 3.3% single-dose weight loss.